Kempharm Stock Executives

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Kempharm employes about 22 people. The company is managed by 10 executives with total tenure of roughly 72 years, averaging almost 7.0 years of service per executive having 2.2 employees per reported executive. Examination of Kempharm management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Kempharm future performance.
Please see Stocks Correlation.

Search Insiders 

  Travis Mickle  Chairman
Founder, Chairman, CEO and President and Member of Scientific and Medical Advisory Board
  Sven Guenther  President
Executive Vice President -Research and Development
  Timothy Sangiovanni  President
Principal Accounting Officer, Vice President Corporate Controller

Kempharm Management Team Effectiveness

Kempharm has return on total asset (ROA) of 6.45 % which means that it generated profit of $6.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (222.16) %, meaning that it created substantial loss on money invested by shareholders. Kempharm management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Equity is estimated to increase to 0.20, while Return on Average Assets are projected to decrease to (1.26) . Kempharm Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 2.83 Million. The current Asset Turnover is estimated to increase to 1.26, while Return on Average Assets are projected to decrease to (1.26) .

Kempharm Quarterly Total Assets

90.44 MillionShare
Kempharm Weighted Average Shares is most likely to increase significantly in the upcoming years. The last year's value of Weighted Average Shares was reported at 3.98 Million. The current Weighted Average Shares Diluted is estimated to increase to about 4.3 M, while Issuance Purchase of Equity Shares is projected to decrease to roughly 22.8 M.

Kempharm Workforce Comparison

Kempharm is rated fourth overall in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 810. Kempharm holds roughly 22.0 in number of employees claiming about 2.72% of stocks in Biotechnology industry.

Kempharm Profit Margins

The company has Profit Margin (PM) of (74.21) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 21.98 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.22.

Kempharm Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kempharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kempharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Kempharm insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Kempharm Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Kempharm Price Series Summation is a cross summation of Kempharm price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Kempharm Notable Stakeholders

A Kempharm stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kempharm often face trade-offs trying to please all of them. Kempharm's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kempharm's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Travis Mickle - Founder, Chairman, CEO and President and Member of Scientific and Medical Advisory BoardProfile
Sven Guenther - Executive Vice President -Research and DevelopmentProfile
Timothy Sangiovanni - Principal Accounting Officer, Vice President Corporate ControllerProfile
LaDuane Clifton - CFOProfile
David Tierney - Independent DirectorProfile
Joseph Saluri - Independent DirectorProfile
Matthew Plooster - Independent DirectorProfile
Richard Pascoe - Lead Independent DirectorProfile
Danny Thompson - Independent DirectorProfile
Gordon Johnson - Chief Bus. OfficerProfile

About Kempharm Management Performance

The success or failure of an entity such as Kempharm often depends on how effective the management is. Kempharm management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kempharm management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kempharm management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Average Assets(1.17) (1.26) 
Return on Average Equity 0.20  0.20 
Return on Invested Capital(0.41) (0.44) 
Return on Sales(0.60) (0.65) 
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
The data published in Kempharm's official financial statements usually reflect Kempharm's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Kempharm. For example, before you start analyzing numbers published by Kempharm accountants, it's critical to develop an understanding of what Kempharm's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Kempharm's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kempharm's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Kempharm's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kempharm. Please utilize our Beneish M Score to check the likelihood of Kempharm's management to manipulate its earnings.

Kempharm Workforce Analysis

Traditionally, organizations such as Kempharm use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kempharm within its industry.

Kempharm Manpower Efficiency

Return on Kempharm Manpower

Revenue Per Employee1.1 M
Revenue Per Executive2.3 M
Net Loss Per Employee2.5 M
Net Loss Per Executive5.5 M
Working Capital Per Employee2.1 M
Working Capital Per Executive4.6 M
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bond Directory
Find actively traded corporate debentures issued by US companies
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.